Xencor, Inc.
XNCR
Positions held
Your positionsXNCR isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Xencor, Inc. operates in a competitive biotechnology industry with a strong focus on innovative therapies, positioning itself well for future growth.
- Revenue increased by 1034% compared to the prior quarter, reaching $51 million from $4.5 million.
- The operating margin improved to -72.4%, indicating a positive trend in operational efficiency.
- The company has a negative profit margin of -1.56%, reflecting ongoing challenges in achieving profitability.
- In 2025, Xencor reported a net income loss of $91.923 million, highlighting significant financial struggles.
- The current ratio stands at 6.39, indicating potential liquidity issues despite a high level of current assets.
Fundamentals
| Market cap | $1.82B | Enterprise value | $1.54B | Trailing P/E | — | Forward P/E | -6.89 |
| PEG | — | Price / book | 3.62 | Beta | 0.90 | Dividend yield | 0.00% |
| Revenue growth | 17.5% | Earnings growth | — | Gross margin | -143.6% | Operating margin | -72.4% |
| Profit margin | -1.6% | ROE | -29.1% | ROA | -16.8% | Debt / equity | 0.34 |
| Current ratio | 6.39 | Free cash flow | -$94.54M | Analyst recommendation | strong_buy | Mean target | $31.42 |
| 52w high | $30.61 | 52w low | $10.38 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $51.2M | $4.5M | $28.2M | $21.0M | $43.6M |
| Op margin | -72.4% | -1724.1% | -189.9% | -226.3% | -76.1% |
| Net income | -$21.7M | -$129M | -$6.7M | -$6.0M | -$30.8M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$37.1M | -$77.9M | -$53.6M | -$47.5M | -$33.2M |
- Revenue +1034% vs prior quarter ($51M vs $4.5M).
- Operating margin expanded to -72.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $126M | $110M | $175M | $165M |
| Op margin | -141.4% | -161.5% | -75.8% | -50.1% |
| Net income | -$91.9M | -$233M | -$133M | -$55.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$178M | -$178M | -$132M | -$82.5M |
Headlines — watch
• [WARN · legal] Xencor Shares Rise After Settlement Deal With Alexion
News
2026-10-01 · Raymond James Updates Healthcare Top Picks for October
2026-09-25 · Xencor's XmAb819 Data Could Support Registrational Path, Wedbush Says
2026-09-21 · BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating
2026-09-07 · Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
2026-09-02 · Xencor to Present at the 2026 Cantor Global Healthcare Conference
2026-09-01 · Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating
2026-08-08 · How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit
2026-08-06 · Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating
2026-08-06 · RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating
2026-08-05 · Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 · Xencor: Q2 Earnings Snapshot
2026-08-05 · Xencor Reports Second Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patterns